MedTrace Logo

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

NCT01356940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-10-31

Study results available
· View outcomes & findings →

Summary

A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis

Conditions

Interventions

DRUG

dalfampridine ER

dalfampridine ER 10mg bid for 4 weeks

DRUG

placebo

identical placebo tablet administered bid for four weeks

Sponsors & Collaborators

  • Acorda Therapeutics

    collaborator INDUSTRY

  • Brown, Theodore R., M.D., MPH

    lead INDIV

Principal Investigators

  • Theodore R Brown, MD · EvergreenHealth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356940 on ClinicalTrials.gov